Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 298

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 298
---
30, 2024, we purchased
FYARRO for either clinical or commercial purposes for use in the United States and Canada. Although we believe we presently have sufficient supply of FYARRO for at least the next two years based on our estimated demand and are seeking to enter into
a new agreement with Fresenius Kabi for the manufacture of FYARRO, if we are unable to enter into a new agreement on favorable terms or at all, our business could be materially adversely affected.

We have supply agreements in place for key raw materials used in the manufacture of FYARRO such as the drug substance sirolimus and for human albumin, which
are key ingredients in the drug product. We do not currently have arrangements in place for redundant supply of the key raw materials used in the manufacture of FYARRO. We expect to continue to evaluate options to cost-effectively produce FYARRO at
contract manufacturing facilities.

We generally expect to rely on third parties for the manufacture or development of any companion diagnostics if we are
required to do so in the future for FYARRO.

Employees and Human Capital

We have operated by leveraging skilled experts, consultants, contract research organizations, and contractors to manage our clinical operations, manufacturing,
research and development, and other functions under the leadership and direction of our management. We will continue to assess expansion of our infrastructure to manage our operations, including the hiring of additional full-time employees.

On August 16, 2024, our board of directors approved a plan of termination that resulted in a workforce reduction of 22 employees, representing
approximately 32% of our workforce. As of September 30, 2024, we had 53 full-time employees, including 34 employees engaged in research and development. None of our employees are represented by labor unions or covered by collective bargaining
agreements. We consider the relationship with our employees to be good.

- 207 -

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining,
incentivizing and integrating our existing and additional employees, advisors and consultants, while being committed to a diverse and dynamic workplace. The principal purposes of our equity incentive plans are to attract, retain and reward personnel
through the granting of equity-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.

Our Corporate Information

We were originally
incorporated in the State of Delaware in November 2007 under the name “Z